PT  - JOURNAL ARTICLE
AU  - Dalal, Jay
TI  - Differential Impact of Dyslipidemia on Chronic Kidney Disease between Men and Women
AID  - 10.1101/2022.06.22.22276767
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.22.22276767
4099  - http://medrxiv.org/content/early/2022/06/28/2022.06.22.22276767.short
4100  - http://medrxiv.org/content/early/2022/06/28/2022.06.22.22276767.full
AB  - Dyslipidemia (DLD), defined as an imbalance of lipids in the blood, is proven to have a strong association with chronic kidney disease (CKD). CKD is more frequent in women than men, although men are more likely to progress to severe stages. Whether sex differences drive the effect of DLD on CKD severity remains unclear. In this study, the relationship between biological sex and CKD severity was investigated by parsing the public electronic health records of 491 CKD patients in Abu Dhabi. Sex-specific relative risks (RRs) were calculated using a history of DLD as a risk factor for severe CKD (stages 3 - 5). The RR was 2.98 (95% CI: 1.78 - 4.18) in women and 2.86 (95 CI%: 2.02 - 3.70) in men. Smoking was identified as a confounding variable because it has a higher incidence in men and a known negative impact on CKD. Thus, we validated the findings in a subsetted group excluding any patient with a history of smoking: the RR was 2.96 (95% CI: 1.76 - 4.16) in women and 2.61 (95% CI: 1.57 - 3.65) in men. These results indicate that, among CKD patients, women with DLD are more likely to progress to severe stages of CKD than men with DLD. The excess risk may be explained by notably higher rates of obesity in women and the idea that women have poorer adherence to DLD medications, although this is newly discovered evidence. Future studies are needed to investigate mechanisms behind this observed disparity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data used was obtained on the website Kaggle and was completely free, usable, and downloadable. The link to the dataset from Kaggle is here: https://www.kaggle.com/datasets/davidechicco/chronic-kidney-disease-ehrs-abu-dhabi.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produces are available online at: https://www.kaggle.com/datasets/davidechicco/chronic-kidney-disease-ehrs-abu-dhabi. https://www.kaggle.com/datasets/davidechicco/chronic-kidney-disease-ehrs-abu-dhabi